[go: up one dir, main page]

BR9912490A - Composto, composição farmacêutica, processo para tratar doenças infecciosas, e uso do composto - Google Patents

Composto, composição farmacêutica, processo para tratar doenças infecciosas, e uso do composto

Info

Publication number
BR9912490A
BR9912490A BR9912490-4A BR9912490A BR9912490A BR 9912490 A BR9912490 A BR 9912490A BR 9912490 A BR9912490 A BR 9912490A BR 9912490 A BR9912490 A BR 9912490A
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
infectious diseases
gram
treating infectious
Prior art date
Application number
BR9912490-4A
Other languages
English (en)
Inventor
Yuko Kano
Toshiro Sasaki
Yumiko Toyooka
Kiyoshi Tanabe
Yoshihisa Akiyama
Hideo Kitagawa
Takahisa Maruyama
Hiromasa Takizawa
Takashi Ando
Kazuhiro Aihara
Kunio Atsumi
Katsuyoshi Iwamatsu
Takashi Ida
Original Assignee
Meiji Seika Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha filed Critical Meiji Seika Kaisha
Publication of BR9912490A publication Critical patent/BR9912490A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/18—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/14—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, PROCESSO PARA TRATAR DOENçAS INFECCIOSAS, E USO DO COMPOSTO". Novos compostos que possuam uma ampla atividade antibacteriana sobre bactérias gram-positivas e gram-negativas em particular, um potente efeito anti-bacteriano sobre a β-lactamase que produz bactéria, MRSA, Pseudomonas aeruginosa tolerante, DRSP, enterococo e Haemophilus influenzae e uma estabilidade extremamente alta ao DHP-1. Estes compostos são aqueles representado pela fórmula geral (I): seus sais farmaceuticamente aceitáveis e ésteres do ácido carboxílico na posição 3 do seu anel de cabapenem.
BR9912490-4A 1998-07-27 1999-07-27 Composto, composição farmacêutica, processo para tratar doenças infecciosas, e uso do composto BR9912490A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21053498 1998-07-27
PCT/JP1999/004025 WO2000006581A1 (en) 1998-07-27 1999-07-27 Novel carbapenem derivatives

Publications (1)

Publication Number Publication Date
BR9912490A true BR9912490A (pt) 2001-06-05

Family

ID=16590961

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9912490-4A BR9912490A (pt) 1998-07-27 1999-07-27 Composto, composição farmacêutica, processo para tratar doenças infecciosas, e uso do composto

Country Status (10)

Country Link
US (2) US6458780B1 (pt)
EP (1) EP1101766A4 (pt)
KR (1) KR20010085302A (pt)
CN (1) CN1315955A (pt)
AR (1) AR019482A1 (pt)
AU (1) AU771876B2 (pt)
BR (1) BR9912490A (pt)
CA (1) CA2338816A1 (pt)
ID (1) ID29173A (pt)
WO (1) WO2000006581A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1101766A4 (en) * 1998-07-27 2001-11-21 Meiji Seika Kaisha NEW CARBAPENEM DERIVATIVES
JP2005231997A (ja) * 2000-01-24 2005-09-02 Meiji Seika Kaisha Ltd カルバペネム誘導体の製造法
AU2883301A (en) * 2000-01-26 2001-08-07 Meiji Seika Kaisha Ltd. Novel carbapenem derivatives of quaternary salt type
DE60106390T2 (de) * 2000-01-26 2005-02-24 Meiji Seika Kaisha Ltd. Neue carbapenem-derivate
MXPA03004331A (es) 2000-11-24 2003-08-19 Meiji Seika Kaisha Derivados novedosos de carbapenem.
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP1582522A4 (en) * 2002-12-13 2007-08-08 Meiji Seika Kaisha INTERMEDIARY FOR SUBSTITUTED CARBAPENEME DERIVED IN POSITION 2 AND METHOD OF PRODUCING THE SAME
DE602006020545D1 (de) 2005-01-19 2011-04-21 Meiji Seika Kaisha Imidazothiazol-derivat und herstellungsverfahren dafür
WO2008012571A1 (en) * 2006-07-24 2008-01-31 Merck Sharp & Dohme Limited Imidazothiazole derivatives as mark inhibitors
WO2008085913A1 (en) * 2007-01-04 2008-07-17 Rib-X Pharmaceuticals, Inc. Methods for treating, preventing, or reducing the risk of opthalmic, otic, and nasal infections
US20120022040A1 (en) * 2008-12-01 2012-01-26 Mutz Mitchell W Antimicrobials
PL221806B1 (pl) * 2013-03-21 2016-05-31 Inst Chemii Bioorg Polskiej Akademii Nauk Sposób wprowadzania acetalowych i acetaloestrowych grup ochronnych oraz związki do realizacji tego sposobu
US10526343B2 (en) * 2018-03-26 2020-01-07 University Of Sharjah Heterocyclic systems and pharmaceutical applications thereof
CN114790157B (zh) * 2022-02-28 2024-06-21 开封大地农化生物科技有限公司 一种高含量乙蒜素的合成方法
CN114805280B (zh) * 2022-05-17 2023-06-02 苏州华一新能源科技股份有限公司 碳酸亚乙烯酯的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10507185A (ja) * 1994-10-14 1998-07-14 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ２−（イミダゾール−４−イル）カルバペネム誘導体、その中間体および抗菌剤としての使用
JP3527003B2 (ja) * 1995-03-10 2004-05-17 明治製菓株式会社 新規イミダゾ［５，１−ｂ］チアゾール誘導体
ES2179932T3 (es) * 1995-03-10 2003-02-01 Meiji Seika Co Nuevos derivados de carbapenem.
JPH09249667A (ja) * 1996-01-12 1997-09-22 Takeda Chem Ind Ltd カルバペネム化合物、その製造法および剤
ES2181159T3 (es) * 1997-01-28 2003-02-16 Meiji Seika Kaisha Nuevos derivados de carbapenem.
EP1101766A4 (en) * 1998-07-27 2001-11-21 Meiji Seika Kaisha NEW CARBAPENEM DERIVATIVES
DE60106390T2 (de) * 2000-01-26 2005-02-24 Meiji Seika Kaisha Ltd. Neue carbapenem-derivate
AU2883301A (en) * 2000-01-26 2001-08-07 Meiji Seika Kaisha Ltd. Novel carbapenem derivatives of quaternary salt type
MXPA03004331A (es) * 2000-11-24 2003-08-19 Meiji Seika Kaisha Derivados novedosos de carbapenem.

Also Published As

Publication number Publication date
US6677331B2 (en) 2004-01-13
US6458780B1 (en) 2002-10-01
EP1101766A4 (en) 2001-11-21
AU771876B2 (en) 2004-04-01
CN1315955A (zh) 2001-10-03
CA2338816A1 (en) 2000-02-10
ID29173A (id) 2001-08-09
EP1101766A1 (en) 2001-05-23
KR20010085302A (ko) 2001-09-07
US20030149016A1 (en) 2003-08-07
WO2000006581A1 (en) 2000-02-10
AU4802499A (en) 2000-02-21
AR019482A1 (es) 2002-02-20

Similar Documents

Publication Publication Date Title
BR9912490A (pt) Composto, composição farmacêutica, processo para tratar doenças infecciosas, e uso do composto
BRPI0410477A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto
BR9714269A (pt) Composto, composição farmacêutica, e, processos para controlar uma infecção bacteriana em um mamìfero e para a preparação de compostos macrólidos tricìclicos
AR005597A1 (es) Derivados de benzoxazina , composiciones farmaceuticas para el tratamiento de infecciones bacterianas, y metodo para la preparacion de dichos derivados.
AU3437695A (en) New piperidine compounds, process for their preparation and the pharmaceutical compositions which contain them
BR9806870A (pt) Composto, processo para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, formulação farmacêutica, e, uso de um composto e processo para preparar o mesmo.
TR199901127T2 (xx) Antibakteriyel etkili 6-O-ikameli ketolitler.
BRPI9810519A (pt) derivados de 4''-substituído-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos.
ES2170080T3 (es) Derivados de 2-(1-(1,3-tiazolin-2-il)azetidin-3-il)tio-carbapenem.
BR0109854A (pt) Processo para produção de perciquinina e seu uso como produto farmacêutico
BR0209821A (pt) Compostos, processo para a manufatura desses compostos, composições farmacêuticas que compreendem os mesmos, processo para o tratamento e/ou profilaxia de enfermidades e utilização dos compostos
BR0114321A (pt) Composto, composição farmacêutica, uso de um composto, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar um composto
BRPI0307267B8 (pt) uso de compostos inibidores de beta-lactamases e composições farmacêuticas para terapia antibacteriana
BR0213539A (pt) Compostos, processo para a preparação de compostos, composições farmacêuticas que compreendem um composto método para o tratamento e/ou profilaxia de enfermidades que estão associadas com dpp iv e utilização desses compostos
BR9303235A (pt) Compostos e processo para sua preparacao,formulacao farmaceutica,metodo para o combate de bacterias e metodo para o tratamento de infecoes bacterianas
BR9812577A (pt) Composto, processo para preparar o mesmo, composição farmacêutica, e, processo para tratar infecções bacterianas
BR9813317A (pt) Composto, composição farmacêutica para tratar infecções bacterianas, e, processos para tratar infecções bacterianas, e para preparar um composto
BRPI0406717A (pt) Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção
BRPI9915480B8 (pt) azalídeos de 13 membros, composições farmacêuticas compreendendo os mesmos, método para sua preparação bem como seus usos.
BG105543A (en) Novel macrolide antibiotics
BR0316690A (pt) Composto, prodroga, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
BR9812148A (pt) Derivados de eritromicina 6,9-ligados em ponte
BR9813319A (pt) Composto, composição farmacêutica para tratamento de infecções bacterianas, e, processos para tratar infecções bacterianas e para preparar um composto
RU94030236A (ru) Производные 3 бета-алкенил-пенама, способ их получения, лекарственные средства и их применение для борьбы и предупреждения болезней
BR9814498A (pt) Processo para o tratamento de obesidade em um humano necessitando de tal tratamento, composto, uso do mesmo, produto, e, composição farmacêutica

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]